Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced today the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The Hamburg-based physicist and expert in spectroscopy brings a wealth of scientific knowledge in modern spectroscopic methods and materials research to the company's advisory team.
Uwe Perbandt, CEO of Viromed Medical AG, commented, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg, where he also serves as the Institute's Managing Director. He is affiliated with the Center for Free-Electron Laser Science (CFEL) and conducts research using large-scale facilities such as PETRA III and FLASH. His work focuses on modern spectroscopic techniques, including Raman spectroscopy and ellipsometry, applied to the study of superconductors, quantum materials, and biological and inorganic samples.
With over 180 publications and approximately 4,000 citations, Prof. Rubhausen has contributed to prestigious journals like Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, he is developing AI-supported analysis workflows for complex datasets, a skill that may prove valuable in analyzing the effects of cold plasma on various materials.
This appointment underscores Viromed's commitment to advancing cold plasma technology in medicine. By integrating deep scientific expertise into its advisory structure, Viromed aims to better understand the interaction between plasma and biological tissues, potentially leading to innovative therapeutic applications. Cold plasma, which has been used for wound healing and disinfection, holds promise for broader medical uses, and having a physicist of Prof. Rubhausen's caliber on board could accelerate research and development.
Viromed Medical AG, listed on the stock exchange since October 2022, operates through its subsidiary Viromed Medical GmbH, focusing on the distribution of cold plasma medical products. The company has a broad customer base in the DACH region and beyond, and this strategic addition to its Medical Advisory Board aligns with its growth objectives.
Prof. Rubhausen's interdisciplinary approach and experience with advanced spectroscopic methods may provide insights into how cold plasma affects materials at a fundamental level, potentially leading to improved product efficacy and safety. His appointment is a signal of Viromed's dedication to rigorous scientific validation of its technologies.
For more information about Viromed Medical AG, visit their website. The original press release can be accessed at newmediawire.com.
